Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 718

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 718
---
 deliver a separate copy of this proxy statement/prospectus to any shareholder at a shared address to which a single copy of each document was delivered and who wishes to receive separate copies of such documents. Shareholders receiving multiple copies of such documents may likewise request that Denali deliver single copies of such documents in the future. Shareholders receiving multiple copies of such documents may request that Denali deliver single copies of such documents in the future. Shareholders may notify Denali of their requests by calling or writing Denali Capital Acquisition Corp. at (646) 978-5180 or at its principal executive offices at 437 Madison Avenue, 27 Floor, New York, NY 10022. Following the Business Combination, such requests should be made by writing or calling Semnur Pharmaceuticals, Inc. at 960 San Antonio Road, Palo Alto, CA 94303, Attn: Corporate Secretary.

<div align='center'>**453

WHERE YOU CAN FIND MORE INFORMATION**</div>

Denali has filed this proxy statement/prospectus as part of a registration statement on a Form S-4 with the SEC under the Securities Act. This proxy statement/prospectus does not contain all of the information included in the registration statement. For further information pertaining to Denali and its securities, you should reference the registration statement and its exhibits. The descriptions in this proxy statement/prospectus of the provisions of documents filed as exhibits to this proxy statement/prospectus are only summaries of those documents’ material terms. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by Denali with the SEC at the SEC’s website at http://www.sec.gov. If you would like additional copies of this proxy statement/prospectus or if you have questions about the Business Combination or the Proposals to be presented at the Meeting, you should contact our proxy solicitor at the following address and telephone number:

<div align='center'>P.O. Box 10904

Yakima, WA 98909

Toll-Free: 877 870-8565

Collect: (206) 870-8565

Email: ksmith@advantageproxy.com</div>

If you are a shareholder of Denali and would like to request documents, please do so by , , in order to receive them before the Meeting. If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means.

Information and statements contained in this proxy statement/prospectus are